SCHEMBL13079792

SCHEMBL13079792

CCc1ccc(CC(=O)OC)cc1[N+](=O)[O-]

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.52
FGFR1 P11362 1/20 0.52
PDGFRA P16234 1/20 0.52
FLT1 P17948 1/20 0.52
FGFR3 P22607 1/20 0.52
KDR P35968 1/20 0.52
PDK1 Q15118 1/20 0.49
ALDH1A1 P00352 5/20 0.47
GAA P10253 1/20 0.47
GFER P55789 1/20 0.47
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
LMNA P02545 1/20 0.43
HSP90AB1 P08238 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16412469 0.93 PDGFRB (0.57) PDGFRBFGFR1PDGFRAFLT1FGFR3
Butane SCHEMBL16413391 0.92 PDGFRB (0.53) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL5092015 0.87 LMNA (0.49) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL31170840 0.84 ALDH1A1 (0.59) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL20045093 0.84 PDGFRB (0.53) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL286994 0.84 ALDH1A1 (0.59) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL731999 0.82 MEN1 (0.56) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL29875166 0.82 ALDH1A1 (0.55) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL7235742 0.82 ALDH1A1 (0.47) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL7425083 0.82 ALDH1A1 (0.57) PDGFRBFGFR1PDGFRAFLT1FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY Lhotse Bio, Inc (US) 2024-01-18 US disclosed
US-20100292458-A1 NOVEL PHOTOLABILE PROTECTIVE GROUPS FOR IMPROVED PROCESSES TO PREPARE OLIGONUCLEOTIDE ARRAYS NIGU CHEMIE GMBH (DE) 2010-11-18 US disclosed
US-7759513-B2 Photolabile protective groups for improved processes to prepare oligonucleotide arrays NIGU CHEMIE GMBH (DE) 2010-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018102-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LPAR1, LPAR2, LPAR5 PDGFRB 529/4885FGFR1 179/4885PDGFRA 551/4885
US-20100292458-A1 NOVEL PHOTOLABILE PROTECTIVE GROUPS FOR IMPROVED PROCESSES TO PREPARE OLIGONUCLEOTIDE ARRAYS NT5C3B, NSUN2, ERCC4 PDGFRB 3988/4885FGFR1 4550/4885PDGFRA 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.